Results 151 to 160 of about 5,783,535 (228)

Veille numérique - n° 23

Numérique et recherche en histoire de l'art, 2021
openaire   +1 more source

Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study. [PDF]

Cardiol Ther
Tian Z, Li X, Li L, Zhang Q, Wang J, Shi Y, Peng D, Ma W, Yang P, Cheng X, Jin W, Wang F, Memaj A, Xie Y, Pan B, Florea V, Zheng J, Zhong Y, Zhang S.   +18 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Eisosomal proteins are essential for plant-fungal interaction of Neurospora crassa and the sweetgrass Brachypodium distachyon. [PDF]

Sci Rep
Winter H, Kempken F.
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Boletín informativo N°23

, 2019
Este boletín informativo, correspondiente al mes de mayo del 2019, muestra casos de diversas enfermedades en la red de hospitales de EsSalud a nivel nacional, durante la Semana Epidemiológica N°19.
openaire   +1 more source

Seventy-Two-Hour Emergency Department Revisits in the Pediatric Population at King Abdullah Specialist Children's Hospital, Riyadh, Saudi Arabia: A Morbidity Analysis. [PDF]

Int J Pediatr
AlAteeq M, Althuwaini S, Alsubaie H, Al-Alshaikh L, Alotaibi G, Alghuraybi S, Omair A.   +6 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Hidden Costs of Workflow Challenges in Endoscopy Units: Insights from a Multinational Survey. [PDF]

Endosc Int Open
Beilenhoff U, Schlag C, Wichmann D.
europepmc   +1 more source